Transjugular Intrahepatic Portosystemic Shunt: A Possible Risk Factor for Direct‐Acting Antiviral Treatment Failure in Patients With Hepatitis C?
Felix Piecha, Jan‐Michael Gänßler, Sabine Jordan, Can Ergen, Harald Ittrich, Johannes Kluwe, Sven Pischke, Ansgar W. Lohse, Julian Schulze zur Wiesch – 18 March 2019 – Direct‐acting antiviral (DAA) therapies have revolutionized the treatment of chronic hepatitis C virus infection, achieving sustained virological response (SVR) rates of >90% even in patients with advanced liver cirrhosis.